Adjuvant Olaparib in BRCA-Mutated Breast Cancer

To the Editor: In the OlympiA trial involving patients with early breast cancer and BRCA1 or BRCA2 germline mutation reported by Tutt et al. (June 10 issue),(1) patients received 1 year of olaparib or placebo. Adjuvant olaparib significantly improved both invasive disease-free survival and distant disease-free survival. In addition, olaparib lowered the recurrence of local lesions, as well as contralateral breast cancer and a second primary ovarian cancer. Prophylactic surgery in patients with BRCA mutation is also known to reduce the risk of breast cancer,(2) with reduced mortality by simultaneously performing bilateral salpingo-oophorectomy.(3) In the OlympiA trial, which included patients . . .

Automated summary

The OlympiA trial showed that adjuvant olaparib significantly improved invasive and distant disease-free survival rates for early breast cancer patients with BRCA1 or BRCA2 mutations. It also reduced recurrence of local lesions and lowered the risk of contralateral breast cancer and second primary ovarian cancer through prophylactic surgery.